PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Bespak Achieves Sustainability Milestone with First Life Cycle Assessment for Pressurised Metered Dose Inhaler valve

Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO), today announced that it has completed its first life cycle assessment (LCA) for its market-leading BK357 pressurised Metered Dose Inhaler (pMDI) valve. This important step comes as a result of Bespak’s commitment to looking beyond low Global Warming Potential (GWP) propellants for opportunities to reduce carbon footprint in the pharma industry.

The completion of Bespak’s first LCA marks a significant milestone that has been achieved as part of Bespak’s overarching sustainability strategy. It follows Bespak’s investment in manufacturing capabilities at clinical and commercial scale for low carbon pMDIs incorporating the low GWP propellants, HFA-152a & HFO-1234ze.

The project was undertaken to better understand the carbon impact of Bespak’s materials and manufacturing processes, and to increase transparency in the supply chain for pMDIs. The LCA has been independently verified by expert sustainability scientists from Tunley Environmental in line with ISO 14067:2018 standards. A verified LCA certification for industry partners using the BK357 valve will enable them to leverage robust, science-led insights that can support transparency in their sustainability reporting, sustainable procurement frameworks and the transition to net zero carbon emissions. The LCA also provides clear direction for future carbon reduction initiatives at Bespak, including emission-saving opportunities in the material and energy stages of the product life cycle.

Chris Hirst, CEO of Bespak, said: “The completion of the LCA for our widely used and trusted BK357 pMDI valve demonstrates Bespak’s active commitment to championing sustainability in the supply chain for the benefit of customers, patients and the planet. We are excited to be actively researching solutions for carbon reduction beyond the propellant switch, and are proud to provide credible, independently verified data to back up our environmental claims.”

Benedicta Bakpa, Head of ESG at Bespak, commented: “This important milestone signifies our ongoing commitment to transparency and accountability in driving sustainable operations. As part of our overarching sustainability initiatives, we continue to identify opportunities to reduce our carbon footprint and work towards our near- and long-term net zero targets.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026